NASDAQ:NRXP NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free NRXP Stock Alerts $3.23 +0.05 (+1.57%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$3.02▼$3.2450-Day Range$2.06▼$66.9052-Week Range$1.90▼$12.00Volume181,829 shsAverage Volume311,911 shsMarket Capitalization$34.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get NRx Pharmaceuticals alerts: Email Address Ad Weiss RatingsTiny AI projects with huge promise hiding in plain sight …I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars.Click here to find out who they are. About NRx Pharmaceuticals Stock (NASDAQ:NRXP)NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Read More NRXP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRXP Stock News HeadlinesMay 15 at 9:41 AM | msn.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2024 Earnings Call TranscriptMay 15 at 4:38 AM | finanznachrichten.deNRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15 at 4:38 AM | finance.yahoo.comNRX Pharmaceuticals Inc (NRXP) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 14 at 9:04 PM | investorplace.comNRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024May 14 at 4:01 PM | prnewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 13 at 9:37 AM | msn.comNRx Pharmaceuticals to Unveil First Quarter Financial Results and Corporate UpdateMay 13 at 4:36 AM | msn.comNRx Pharmaceuticals Makes Significant Stride with New Depression Drug, Aims for Accelerated FDA ApprovalMay 12, 2024 | americanbankingnews.comNRx Pharmaceuticals (NRXP) to Release Earnings on TuesdayMay 8, 2024 | markets.businessinsider.comNRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone UpdateMay 8, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024May 7, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024May 6, 2024 | marketwatch.comNRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial DataMay 6, 2024 | markets.businessinsider.comNRx Pharmaceuticals Plans To Seek Accelerated Approval Of NRX-101 - Quick FactsMay 6, 2024 | prnewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar DepressionApril 30, 2024 | prnewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar DepressionApril 18, 2024 | investorplace.comWhy Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?April 18, 2024 | finance.yahoo.comNRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common StockApril 18, 2024 | finance.yahoo.comNRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price RequirementApril 18, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price RequirementApril 18, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common StockApril 17, 2024 | markets.businessinsider.comNRx Pharmaceuticals: New Data Demonstrates No Impact Of NRX-101 On Gut Or Vaginal FloraApril 17, 2024 | finance.yahoo.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infectionsApril 15, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)April 14, 2024 | msn.comNRx Pharmaceuticals Advances in Breakthrough Bipolar Depression TreatmentApril 8, 2024 | markets.businessinsider.comNRx Pharma Achieves Data-lock In Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression StudySee More Headlines Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/15/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRXP CUSIPN/A CIK1719406 Webwww.bigrockpartners.com Phone(484) 254-6134FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,150,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-202.53% Debt Debt-to-Equity RatioN/A Current Ratio0.36 Quick Ratio0.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.38) per share Price / Book-2.34Miscellaneous Outstanding Shares10,560,000Free Float8,332,000Market Cap$34.11 million OptionableOptionable Beta1.15 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Jonathan C. Javitt M.D. (Age 67)M.P.H., Co-Founder, Chief Scientist Officer & Chairman Comp: $873.7kMr. Stephen H. Willard Esq. (Age 63)Acting Corporate Secretary, CEO & Director Comp: $501.19kDr. Riccardo Panicucci Ph.D. (Age 62)Chief Technology Officer Comp: $240kDr. Seth L. Van Voorhees Ph.D. (Age 63)Treasurer Comp: $399.96kMr. Richard Clavano Narido (Age 46)Interim CFO, Principal Financial Officer & Principal Accounting Officer Suzanne MessereInvestor RelationsDr. Philip T. Lavin Ph.D. (Age 77)Chief Methodologist Dr. Dennis K. McBride Ph.D.Chief Strategy Officer & Senior ScientistMr. Matthew Patrick Duffy (Age 61)Chief Business Officer More ExecutivesKey CompetitorsBriaCell TherapeuticsNASDAQ:BCTXFortress BiotechNASDAQ:FBIOSpruce BiosciencesNASDAQ:SPRBAcurx PharmaceuticalsNASDAQ:ACXPAprea TherapeuticsNASDAQ:APREView All CompetitorsInsidersAaron GorovitzBought 3,500 shares on 8/30/2023Total: $11,200.00 ($3.20/share)Jonathan C JavittBought 20,000 shares on 8/22/2023Total: $64,000.00 ($3.20/share)View All Insider Transactions NRXP Stock Analysis - Frequently Asked Questions How have NRXP shares performed in 2024? NRx Pharmaceuticals' stock was trading at $46.00 at the beginning of 2024. Since then, NRXP shares have decreased by 93.0% and is now trading at $3.23. View the best growth stocks for 2024 here. When is NRx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our NRXP earnings forecast. How were NRx Pharmaceuticals' earnings last quarter? NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) posted its earnings results on Friday, March, 29th. The company reported ($0.50) EPS for the quarter. What ETF holds NRx Pharmaceuticals' stock? AdvisorShares Psychedelics ETF holds 105,043 shares of NRXP stock, representing 4.75% of its portfolio. When did NRx Pharmaceuticals' stock split? NRx Pharmaceuticals's stock reverse split on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What guidance has NRx Pharmaceuticals issued on next quarter's earnings? NRx Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 28th. The company provided EPS guidance of -0.400--0.400 for the period, compared to the consensus estimate of -0.370. The company issued revenue guidance of -. How do I buy shares of NRx Pharmaceuticals? Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRXP) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsTop 5 AI Stocks to Buy for 2024Market Moving TrendsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 Tech Stocks to Buy for 2024Daily Market AlertsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.